People with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, pancreatitis, or severe gastrointestinal conditions should avoid GLP1 weight-loss drugs unless specifically advised by their physician
Insurers find themselves in the position of needing to say "yes" or "no" to GLP-1 drugs as more people seek them for weight loss
Verified Market Reports
IF is praised for benefits like improved insulin sensitivity, fat loss, and metabolic health
Med 204 , 16531664 (2007)
Therefore, we have suggested that doctors [do] not need to hold this medication from patients unless they have underlying eye conditions. Novo Nordisk, the maker of Ozempic, Wegovy and Saxenda, said patient safety is a top priority and that it continuously monitor[s] the safety profile of our medicines in collaboration with the TGA and other regulators worldwide